Skip to Main Content
Menu
Close
About Us
Science & Pipeline
Publications and Presentations
Join Us
News
Contact Us
Press Releases
Pretzel Therapeutics Presents Preclinical Data on PX578 at MDA 2026, Further Supporting Clinical Advancement in Individuals Living with POLG Disease
March 11, 2026
Pretzel Therapeutics Presents Preclinical Data Supporting POLRMT as a Novel Target for the Treatment of Metabolic Disease at ObesityWeek 2025
November 4, 2025
Pretzel Therapeutics Strengthens Leadership with Appointment of Ashish Dugar, Ph.D., MBA as Chief Development Officer
September 3, 2025
Pretzel Therapeutics Announces Publication in Nature unveiling discovery of novel small molecule activators for the treatment of POLG disorders and other conditions related to mtDNA depletion
April 9, 2025
Pretzel Therapeutics Initiates Phase 1 Clinical Study Evaluating PX578, Lead Therapeutic in its Bioenergetics Restoration Franchise
April 3, 2025
Pretzel Therapeutics Launches With $72.5 Million Series A Financing to Pioneer Mitochondrial Therapies
September 12, 2022
